Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870103 · ClinicalTrials.gov registry record · Phase 4
Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
A Phase 4 study of Cataract, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT00870103: Completed Phase 4 study of Cataract, sponsored by Alcon Research.
NCT00870103 is a Phase 4 study of Cataract that has completed, run by Alcon Research. The registered enrollment target is 64 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00870103, a Phase 4 study of Cataract, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
Primary Outcome
The percentage of patients with a score of zero for Anterior chamber cells. Anterior chamber inflammation was evaluated based on the number of cells per high-power field measured using the narrowest slit beam of the lamp (0.5 at a height of 8mm). Anterior chamber cells was recorded on a 0-4 point scale,0 = Less than 5 cells; 1 = Mild: 5-10 cells; 2 = Moderate:11-20 cells; 3 = Marked: 21-50 cells; 4 = Severe: Greater than 50 cells / hypopyon
Conditions Studied
Interventions
- DRUG Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Study Locations (1)
Texas
- Alcon Call Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-09 |
| Phase | Phase 4 |
What the finished NCT00870103 record still lists
NCT00870103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops is the first listed.
NCT00870103 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00870103 about?
NCT00870103 is a clinical study titled "Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery". To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
What is the current status of trial NCT00870103?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2008-09.
What conditions does trial NCT00870103 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT00870103?
The interventions under investigation include: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops (DRUG).
Who is sponsoring clinical trial NCT00870103?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00870103 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00870103's enrollment target sits among peer trials
64 52nd of 83 higher than 31 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
RECRUITING · Phase 4
-
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
RECRUITING · Phase 4
-
Evaluation of a Monofocal Intraocular Lens
RECRUITING · Phase 4
-
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
RECRUITING · Phase 4
-
Odyssey Evaluation in Post LASIK Patients
RECRUITING · Phase 4
-
Dropless vs. Standard Drops Contralateral Eye Study
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia